| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.46B | 291.79 | 97.26 | 473.02% | 53.3% | 17.48% | 1.41% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.77B | 56.08 | 25.38 | 17.97% | 16.82% | 8.59% | 4.41% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.39B | 22.80 | 9.74 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.32B | 24.07 | -3.83 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.87B | 17.45 | -5.18 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.59B | 28.93 | -7.09 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.59B | 35.41 | -7.73 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.28B | 42.46 | -9.69 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 99.89M | 133.59M | 154.94M | 164.25M | 175.34M | 198.32M | 131.84M | 109.46M | 145.24M | 233.18M |
| Revenue Growth % | 2.54% | 0.34% | 0.16% | 0.06% | 0.07% | 0.13% | -0.34% | -0.17% | 0.33% | 0.61% |
| Cost of Goods Sold | 2.19M | 4.55M | 3.6M | 5.53M | 5.23M | 6.13M | 3.82M | 4.42M | 11.45M | 7.74M |
| COGS % of Revenue | 0.02% | 0.03% | 0.02% | 0.03% | 0.03% | 0.03% | 0.03% | 0.04% | 0.08% | 0.03% |
| Gross Profit | 97.71M | 129.04M | 151.33M | 158.72M | 170.1M | 192.19M | 128.02M | 105.04M | 133.79M | 225.43M |
| Gross Margin % | 0.98% | 0.97% | 0.98% | 0.97% | 0.97% | 0.97% | 0.97% | 0.96% | 0.92% | 0.97% |
| Gross Profit Growth % | 2.54% | 0.32% | 0.17% | 0.05% | 0.07% | 0.13% | -0.33% | -0.18% | 0.27% | 0.68% |
| Operating Expenses | 129.97M | 168.87M | 182.13M | 227.41M | 269.91M | 368.36M | 327.44M | 424.85M | 521.93M | 549.26M |
| OpEx % of Revenue | 1.3% | 1.26% | 1.18% | 1.38% | 1.54% | 1.86% | 2.48% | 3.88% | 3.59% | 2.36% |
| Selling, General & Admin | 79.54M | 98.02M | 103.96M | 103.65M | 128.95M | 135.8M | 126.28M | 197.52M | 265.54M | 264.12M |
| SG&A % of Revenue | 0.8% | 0.73% | 0.67% | 0.63% | 0.74% | 0.68% | 0.96% | 1.8% | 1.83% | 1.13% |
| Research & Development | 50.43M | 70.85M | 78.17M | 123.76M | 140.96M | 131.77M | 201.16M | 227.33M | 244.99M | 282.7M |
| R&D % of Revenue | 0.5% | 0.53% | 0.5% | 0.75% | 0.8% | 0.66% | 1.53% | 2.08% | 1.69% | 1.21% |
| Other Operating Expenses | -296K | -264K | 1.11M | -474K | -314K | 100.79M | 0 | 0 | 11.39M | 2.44M |
| Operating Income | -50.75M | -58.21M | -53.79M | -80.04M | -99.81M | -176.16M | -199.43M | -319.81M | -388.14M | -323.83M |
| Operating Margin % | -0.51% | -0.44% | -0.35% | -0.49% | -0.57% | -0.89% | -1.51% | -2.92% | -2.67% | -1.39% |
| Operating Income Growth % | 0.36% | -0.15% | 0.08% | -0.49% | -0.25% | -0.76% | -0.13% | -0.6% | -0.21% | 0.17% |
| EBITDA | -37.36M | -42.08M | -35.99M | -61.37M | -79.4M | -151.58M | -186.68M | -299.09M | -349.61M | -280.27M |
| EBITDA Margin % | -0.37% | -0.31% | -0.23% | -0.37% | -0.45% | -0.76% | -1.42% | -2.73% | -2.41% | -1.2% |
| EBITDA Growth % | 0.5% | -0.13% | 0.14% | -0.71% | -0.29% | -0.91% | -0.23% | -0.6% | -0.17% | 0.2% |
| D&A (Non-Cash Add-back) | 13.39M | 16.14M | 17.8M | 18.67M | 20.41M | 24.58M | 12.75M | 20.72M | 38.53M | 43.55M |
| EBIT | 113.22M | -52.85M | -53.94M | -92.06M | -127.62M | -169.74M | -197.2M | -320.14M | -364.78M | -309.33M |
| Net Interest Income | 7.75M | -759K | -1.19M | -4.31M | -8.77M | -14.05M | -17.69M | -4.74M | 10.43M | 6.63M |
| Interest Income | 7.75M | 3.98M | 3.23M | 5.5M | 10.05M | 5M | 1.99M | 6.28M | 21.77M | 17.82M |
| Interest Expense | 0 | 4.73M | 4.42M | 9.81M | 18.83M | 19.05M | 19.68M | 11.01M | 11.33M | 11.18M |
| Other Income/Expense | 156.22M | -23.86M | -30.19M | -21.83M | -46.64M | -12.63M | -17.46M | -11.34M | 12.03M | 3.32M |
| Pretax Income | 105.47M | -57.58M | -58.36M | -101.87M | -146.45M | -188.79M | -216.88M | -331.15M | -376.11M | -320.51M |
| Pretax Margin % | 1.06% | -0.43% | -0.38% | -0.62% | -0.84% | -0.95% | -1.65% | -3.03% | -2.59% | -1.37% |
| Income Tax | -11.77M | -9.68M | 1.37M | 811K | -21K | -19.36M | 409K | 313K | 223K | 120K |
| Effective Tax Rate % | 1.11% | 0.83% | 1.02% | 1.01% | 1% | 0.9% | 0.83% | 0.84% | 0.3% | 1% |
| Net Income | 117.24M | -47.9M | -59.73M | -102.68M | -146.43M | -169.43M | -180.09M | -278.48M | -111.4M | -321.55M |
| Net Margin % | 1.17% | -0.36% | -0.39% | -0.63% | -0.84% | -0.85% | -1.37% | -2.54% | -0.77% | -1.38% |
| Net Income Growth % | 2.06% | -1.41% | -0.25% | -0.72% | -0.43% | -0.16% | -0.06% | -0.55% | 0.6% | -1.89% |
| Net Income (Continuing) | 117.24M | -47.9M | -59.73M | -102.68M | -146.43M | -169.43M | -217.29M | -331.47M | -376.33M | -320.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 37.2M | 52.99M | 264.93M | -915K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 3.17 | -1.25 | -1.54 | -2.54 | -3.46 | -3.56 | -3.01 | -4.37 | -1.50 | -4.08 |
| EPS Growth % | 1.72% | -1.39% | -0.23% | -0.65% | -0.36% | -0.03% | 0.15% | -0.45% | 0.66% | -1.72% |
| EPS (Basic) | 3.49 | -1.29 | -1.54 | -2.54 | -3.46 | -3.56 | -3.01 | -4.37 | -1.50 | -4.08 |
| Diluted Shares Outstanding | 37.58M | 38.29M | 38.77M | 40.43M | 42.34M | 47.54M | 59.83M | 63.76M | 74.27M | 78.89M |
| Basic Shares Outstanding | 33.56M | 37M | 38.77M | 40.42M | 42.34M | 47.54M | 59.83M | 63.76M | 74.27M | 78.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 301.93M | 332.35M | 325.81M | 495.68M | 429.06M | 410.41M | 582.83M | 486.44M | 616.77M | 416.7M |
| Cash & Short-Term Investments | 229.6M | 255.87M | 300.63M | 471.54M | 398.52M | 361.59M | 552.88M | 450.25M | 566.85M | 370.7M |
| Cash Only | 37.8M | 41M | 99.39M | 102.87M | 62.44M | 84.77M | 165.75M | 61.69M | 58.18M | 58.53M |
| Short-Term Investments | 191.8M | 214.87M | 201.24M | 368.67M | 336.09M | 276.82M | 387.13M | 388.56M | 508.68M | 312.17M |
| Accounts Receivable | 59.31M | 65.36M | 13.87M | 14.49M | 18.05M | 33.07M | 15.91M | 16.65M | 21.18M | 27.12M |
| Days Sales Outstanding | 216.7 | 178.58 | 32.68 | 32.2 | 37.57 | 60.86 | 44.06 | 55.51 | 53.23 | 42.45 |
| Inventory | 2.54M | 2.83M | 5.35M | 5.62M | 6.08M | 7.61M | 7.31M | 4.52M | 9.41M | 6.2M |
| Days Inventory Outstanding | 423.63 | 226.5 | 541.78 | 371.08 | 424.14 | 453.3 | 699.12 | 373.51 | 299.97 | 292.23 |
| Other Current Assets | 2.38M | 4.83M | 5.95M | 2.31M | 5.01M | 0 | 247K | 15.02M | 19.34M | 12.69M |
| Total Non-Current Assets | 210.47M | 192.93M | 194.54M | 213.48M | 175.74M | 197.03M | 193.77M | 186.19M | 172.14M | 177.42M |
| Property, Plant & Equipment | 428K | 2.59M | 3.23M | 3.15M | 9.89M | 9.42M | 34.3M | 30.05M | 25.54M | 19.63M |
| Fixed Asset Turnover | 233.39x | 51.64x | 47.97x | 52.21x | 17.74x | 21.06x | 3.84x | 3.64x | 5.69x | 11.88x |
| Goodwill | 936K | 936K | 936K | 936K | 936K | 936K | 900K | 800K | 753K | 753K |
| Intangible Assets | 161.54M | 182.04M | 184.82M | 186.69M | 157.2M | 153.19M | 147.5M | 96.32M | 103.69M | 103.22M |
| Long-Term Investments | 21.25M | -6.42M | -16.81M | 15M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2M | 7.36M | 5.56M | -25M | 7.71M | 33.49M | 11.07M | 59.03M | 42.16M | 53.82M |
| Total Assets | 512.4M | 525.28M | 520.35M | 709.16M | 604.8M | 607.44M | 776.63M | 672.59M | 788.91M | 594.13M |
| Asset Turnover | 0.19x | 0.25x | 0.30x | 0.23x | 0.29x | 0.33x | 0.17x | 0.16x | 0.18x | 0.39x |
| Asset Growth % | 2.78% | 0.03% | -0.01% | 0.36% | -0.15% | 0% | 0.28% | -0.13% | 0.17% | -0.25% |
| Total Current Liabilities | 85.8M | 83.26M | 85.67M | 104.62M | 95.45M | 92.66M | 124.09M | 142.16M | 177.91M | 200.75M |
| Accounts Payable | 7.64M | 7.52M | 18.94M | 6.95M | 26.61M | 12.13M | 15.14M | 17.29M | 41.67M | 23.53M |
| Days Payables Outstanding | 1.28K | 602.88 | 1.92K | 459.24 | 1.86K | 722.91 | 1.45K | 1.43K | 1.33K | 1.11K |
| Short-Term Debt | 0 | 0 | 0 | 22.46M | 2.61M | 0 | 0 | 0 | 0 | 68.68M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1000K | 0 | 0 | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 72.2M | 68.3M | 58.98M | 64.76M | 52.18M | 62.26M | 39.59M | 47.99M | 94.32M | 100.32M |
| Current Ratio | 3.52x | 3.99x | 3.80x | 4.74x | 4.50x | 4.43x | 4.70x | 3.42x | 3.47x | 2.08x |
| Quick Ratio | 3.49x | 3.96x | 3.74x | 4.68x | 4.43x | 4.35x | 4.64x | 3.39x | 3.41x | 2.04x |
| Cash Conversion Cycle | -635.74 | -197.81 | -1.34K | -55.96 | -1.39K | -208.75 | -704.58 | -998.78 | -975.31 | -774.56 |
| Total Non-Current Liabilities | 126.63M | 134.25M | 141.54M | 286.29M | 288.15M | 303.57M | 350.43M | 487.57M | 410.19M | 334.3M |
| Long-Term Debt | 43.77M | 44.42M | 45.08M | 195.09M | 204.86M | 215.34M | 226.58M | 375.55M | 377.26M | 310.31M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 7.39M | 28.34M | 31.5M | 27.51M | 22.61M | 17.19M |
| Deferred Tax Liabilities | 24.33M | 6.42M | 16.81M | 32.71M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 81.55M | 83.41M | 96.47M | 91.19M | 75.9M | 59.89M | 71.98M | 73.58M | 8.48M | 6.8M |
| Total Liabilities | 212.43M | 217.51M | 227.21M | 390.91M | 383.6M | 396.23M | 474.52M | 629.73M | 588.1M | 535.05M |
| Total Debt | 43.9M | 44.42M | 45.08M | 217.55M | 214.87M | 244.03M | 261.99M | 407.49M | 404.78M | 401.58M |
| Net Debt | 6.1M | 3.42M | -54.32M | 114.67M | 152.43M | 159.26M | 96.23M | 345.8M | 346.61M | 343.05M |
| Debt / Equity | 0.15x | 0.14x | 0.15x | 0.68x | 0.97x | 1.16x | 0.87x | 9.51x | 2.02x | 6.80x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -12.30x | -12.16x | -8.16x | -5.30x | -9.25x | -10.13x | -29.04x | -34.25x | -28.96x |
| Total Equity | 299.97M | 307.77M | 293.13M | 318.25M | 221.2M | 211.21M | 302.11M | 42.85M | 200.81M | 59.08M |
| Equity Growth % | 9.05% | 0.03% | -0.05% | 0.09% | -0.3% | -0.05% | 0.43% | -0.86% | 3.69% | -0.71% |
| Book Value per Share | 7.98 | 8.04 | 7.56 | 7.87 | 5.22 | 4.44 | 5.05 | 0.67 | 2.70 | 0.75 |
| Total Shareholders' Equity | 299.97M | 307.77M | 293.13M | 318.25M | 221.2M | 211.21M | 302.11M | 42.85M | 200.81M | 59.08M |
| Common Stock | 4K | 4K | 4K | 4K | 4K | 5K | 6K | 6K | 7K | 9K |
| Retained Earnings | -65.15M | -113.06M | -177.66M | -270.02M | -416.44M | -585.88M | -765.97M | -1.01B | -1.13B | -1.45B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -682K | -490K | -1.01M | -1.53M | 726K | -902K | -562K | -2.91M | -1.46M | -80K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -554K | -1.6M | 7.4M | -24.96M | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M | -237.47M |
| Operating CF Margin % | -0.01% | -0.01% | 0.05% | -0.15% | -0.33% | -0.22% | -0.11% | -1.7% | -1.93% | -1.02% |
| Operating CF Growth % | 0.99% | -1.88% | 5.64% | -4.37% | -1.33% | 0.27% | 0.65% | -11.59% | -0.5% | 0.15% |
| Net Income | 117.24M | -47.9M | -59.73M | -102.68M | -146.43M | -169.43M | -217.29M | -331.47M | -376.33M | -320.63M |
| Depreciation & Amortization | 13.39M | 16.14M | 17.8M | 18.67M | 20.41M | 24.58M | 12.75M | 20.72M | 38.53M | 43.55M |
| Stock-Based Compensation | 25.9M | 29.1M | 26.87M | 19.77M | 21.11M | 23.61M | 29.57M | 38.14M | 44.25M | 36.91M |
| Deferred Taxes | -15.57M | -22.66M | -6.42M | 20.34M | 0 | 1.99M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -130.14M | 18.26M | 25.07M | 7.86M | 44.08M | 102.54M | 79.41M | 85.44M | 39.01M | 65.71M |
| Working Capital Changes | -11.37M | 5.47M | 3.81M | 11.07M | 2.62M | -26.04M | 80.78M | 875K | -25.48M | -63.02M |
| Change in Receivables | -4.5M | -6.09M | 4.95M | 152K | -4.63M | 2.3M | 17.95M | -1.43M | -11.3M | -6.04M |
| Change in Inventory | -1.17M | -306K | -1.71M | -2.77M | -1.96M | -5.07M | 117K | -1.21M | -39.42M | -3.77M |
| Change in Payables | 3.38M | 9.67M | 2.66M | -2.71M | 9.26M | -6.04M | 2.47M | 2.06M | 24.76M | -17.56M |
| Cash from Investing | -80.6M | 10.37M | 45.6M | -203.29M | 19.86M | -61.33M | -137.62M | -32.55M | 55.78M | 99.33M |
| Capital Expenditures | -7.03M | -11.92M | -14.01M | -19.7M | -195K | -119.84M | -5.1M | -191K | -668K | 0 |
| CapEx % of Revenue | 0.07% | 0.09% | 0.09% | 0.12% | 0% | 0.6% | 0.04% | 0% | 0% | 0.43% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 148.41M | 47.38M | 60.62M | -202.56M | -15.37M | -113.08M | -19.05M | -28.97M | 165.81M | -101.25M |
| Cash from Financing | 100.77M | -5.69M | 5.45M | 231.86M | -2.08M | 127.71M | 231.68M | 117.57M | 218.75M | 139.42M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -2.88M | -5.69M | 5.45M | -3.93M | -2.08M | -3.81M | 6.75M | -6.9M | 27.55M | 4.68M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -7.58M | -13.52M | -6.61M | -44.66M | -73.78M | -162.59M | -38.94M | -214.66M | -321.61M | -338.69M |
| FCF Margin % | -0.08% | -0.1% | -0.04% | -0.27% | -0.42% | -0.82% | -0.3% | -1.96% | -2.21% | -1.45% |
| FCF Growth % | 0.85% | -0.78% | 0.51% | -5.76% | -0.65% | -1.2% | 0.76% | -4.51% | -0.5% | -0.05% |
| FCF per Share | -0.20 | -0.35 | -0.17 | -1.10 | -1.74 | -3.42 | -0.65 | -3.37 | -4.33 | -4.29 |
| FCF Conversion (FCF/Net Income) | -0.00x | 0.03x | -0.12x | 0.24x | 0.40x | 0.25x | 0.08x | 0.67x | 2.51x | 0.74x |
| Interest Paid | 5.84M | 2.07M | 2.07M | 1.88M | 7.67M | 0 | 7.33M | 10.16M | 8.84M | 0 |
| Taxes Paid | 9.61M | 7.93M | 7.17M | 218K | 656K | 0 | 16.42M | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 89.25% | -15.76% | -19.88% | -33.59% | -54.29% | -78.37% | -70.17% | -161.46% | -91.44% | -247.45% |
| Return on Invested Capital (ROIC) | -22.76% | -14.15% | -14.67% | -17.87% | -18.56% | -35.51% | -38.91% | -60.96% | -62.2% | -51.16% |
| Gross Margin | 97.81% | 96.59% | 97.67% | 96.63% | 97.01% | 96.91% | 97.1% | 95.96% | 92.12% | 96.68% |
| Net Margin | 117.36% | -35.86% | -38.55% | -62.51% | -83.51% | -85.43% | -136.6% | -254.41% | -76.7% | -137.9% |
| Debt / Equity | 0.15x | 0.14x | 0.15x | 0.68x | 0.97x | 1.16x | 0.87x | 9.51x | 2.02x | 6.80x |
| Interest Coverage | - | -12.30x | -12.16x | -8.16x | -5.30x | -9.25x | -10.13x | -29.04x | -34.25x | -28.96x |
| FCF Conversion | -0.00x | 0.03x | -0.12x | 0.24x | 0.40x | 0.25x | 0.08x | 0.67x | 2.51x | 0.74x |
| Revenue Growth | 254.19% | 33.74% | 15.98% | 6.01% | 6.75% | 13.11% | -33.52% | -16.97% | 32.69% | 60.55% |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| License | - | - | - | - | - | - | 17.7M | 6.47M |
| License Growth | - | - | - | - | - | - | - | -63.46% |
| Royalty | - | - | - | - | - | - | - | 600K |
| Royalty Growth | - | - | - | - | - | - | - | - |
| Active Pharmaceutical Ingredient | - | - | - | - | - | - | 3.3M | - |
| Active Pharmaceutical Ingredient Growth | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | 210.78M | 200.53M | - | - |
| Product Growth | - | - | - | - | - | -4.86% | - | - |
| Bile Acid Products | 72.63M | 75.07M | 79.7M | 89.44M | 95.65M | 102.56M | - | - |
| Bile Acid Products Growth | - | 3.37% | 6.17% | 12.22% | 6.95% | 7.22% | - | - |
| Tiopronin Products | - | - | - | 108.88M | 115.12M | 97.97M | - | - |
| Tiopronin Products Growth | - | - | - | - | 5.73% | -14.90% | - | - |
| Thiola License | 82.31M | 89.18M | 95.64M | - | - | - | - | - |
| Thiola License Growth | - | 8.34% | 7.25% | - | - | - | - | - |
Travere Therapeutics, Inc. (TVTX) reported $435.8M in revenue for fiscal year 2024.
Travere Therapeutics, Inc. (TVTX) grew revenue by 60.5% over the past year. This is strong growth.
Travere Therapeutics, Inc. (TVTX) reported a net loss of $88.5M for fiscal year 2024.
Travere Therapeutics, Inc. (TVTX) has a return on equity (ROE) of -247.4%. Negative ROE indicates the company is unprofitable.
Travere Therapeutics, Inc. (TVTX) had negative free cash flow of $80.3M in fiscal year 2024, likely due to heavy capital investments.